Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, June 24 at 2:00 PM EDT

Register Free →

This Government Contract opportunity from Department Of Health And Human Services was posted on May 7, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Notice of Intent to Sole Source - Chemistry Center for Combating Antibiotic-Resistant Bacteria (CC4CARB)

Closed
75N93024R00022Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 541714
New
Grant
HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)This contract opportunity from the National Institutes of Health under the Department of Health and Human Services aims to support the development of safe, effective, and non-addictive small molecule and biologic therapeutics for pain treatment. It focuses on accelerating early-stage therapeutic candidates through preclinical optimization to readiness for Phase II clinical trials. Eligible applicants must present a promising lead candidate with strong biological justification and established assays to guide optimization. The funded activities include lead optimization, early development, IND-enabling studies, biomarker development, submission of an Investigational New Drug application, and Phase I clinical testing. The program is structured as a milestone-driven, phased cooperative agreement with active NIH involvement in project planning and monitoring. The solicitation is identified as RFA-NS-27-007, titled HEAL Initiative: Non-addictive Analgesic Therapeutics Development, with clinical trials optional. The solicitation was posted on June 16, 2026, and applicants must respond by February 20, 2029. This federal contract emphasizes collaborative advancement of innovative pain therapeutics while ensuring rigorous oversight from NIH program staff throughout the project lifecycle.
National Institutes Of Health

POSTED

about 21 hours ago

DEADLINE

in over 2 years
NAICS: 541714
New
Federal
TECHNOLOGY LICENSING OPPORTUNITY: DC RecruiterDC Recruiter is an innovative immune-enhancing technology developed by scientists at Los Alamos National Laboratory that uses a self-assembling peptide nanofiber to recruit and activate dendritic cells, critical components of the immune system. Unlike traditional pathogen-specific vaccines and treatments, this approach is designed to trigger an early, broad-spectrum immune response regardless of the specific infectious agent. The product is formulated as a needle-free, spray-friendly application, enhancing its practicality and ease of use in various settings. Its core advantage lies in addressing the challenge of rapid immune activation before the pathogen is identified, providing fast-acting defense during exposure scenarios where conventional methods may be delayed, too specific, or ineffective. This technology holds promise across multiple market sectors, including infectious disease prevention, outbreak management, national defense, consumer health, pharmaceuticals, and emergency preparedness. Its broad, pathogen-agnostic mechanism makes it especially valuable in high-risk or field environments requiring quick deployment and flexible administration. Currently at a technology readiness level of 3, DC Recruitor is patent-pending and available for licensing through Los Alamos National Laboratory’s program, which facilitates exclusive and non-exclusive licensing agreements to commercial partners seeking to leverage cutting-edge innovations for competitive advantage. The ongoing solicitation invites potential collaborators to engage before the stated deadline.
Triad - DOE Contractor

POSTED

2 days ago

DEADLINE

in 6 months
NAICS: 541714
New
Federal
Contact Activation Pathway Function Blocking Antibody AB023The Defense Health Agency is conducting a Request for Information (RFI) to gather market intelligence and identify qualified sources for the supply of the contact activation pathway function blocking antibody AB023, also known as Xisomab 3G3 or Gruticibart. This antibody is designed to inhibit Coagulation Factor XI (FXI) by targeting the "apple 2" domain, preventing its activation by activated factor XII (FXIIa) in the contact pathway, which is implicated in clot formation on artificial surfaces. The antibody is intended for use in medical applications such as Extracorporeal Membrane Oxygenation (ECMO) circuits, hemodialysis, catheters, and cancer-associated thrombosis. It is designed to preserve natural clotting processes by not interfering with FXI activation by thrombin or the conversion of Factor IX by activated FXI, thus maintaining normal hemostasis required for wound healing. The Government anticipates procuring up to 0.5 grams of AB023 annually and requires pharmacokinetic and pharmacodynamic testing to assess its concentration over time, biochemical impacts, clotting time effects, and ability to prevent thrombus growth and fibrin accumulation in vascular thrombosis models. Stability, dosage, and potency validations must be conducted using clotting assays. Although this announcement does not represent a solicitation or obligation to award a contract, interested parties with relevant expertise must submit technical information by June 18, 2026. All responders must be registered in the System for Award Management (SAM). The associated NAICS code is 541714, reflecting research and development in biotechnology. The point of contact is based at the Defense Health Agency in Fort Detrick, Maryland, with the place of performance listed in Texas.
Defense Health Agency

POSTED

5 days ago

DEADLINE

in 1 day

AI Contract Overview

Show more

The NIAID, part of the NIH within the DHHS, is seeking proposals for a contract to establish and operate the Chemistry Center for Combating Antibiotic-Resistant Bacteria (CC4CARB). The center's primary responsibility will be to design, synthesize, test, and manage chemical libraries of small molecules and natural products specifically targeting Gram-negative bacterial pathogens and other antibiotic-resistant bacteria identified as threats by the CDC. This initiative aims to address the critical shortage of novel chemical scaffolds and compound libraries tailored for antibacterial discovery, especially those capable of penetrating Gram-negative bacteria and avoiding human targets, which are currently lacking in existing collections. The contract, expected to start around February 2026, will be a cost-reimbursement, level-of-effort type with an initial one-year base period and four subsequent one-year options, along with additional options for compound management and distribution support extending the total performance period to approximately February 2034. The government estimates a total effort of around 28,000 direct labor hours annually, with the goal of producing approximately 10,000 structurally diverse compounds over the contract duration. Interested parties must submit proposals electronically via the specified NIH portal by November 1, 2024, with the opportunity to contribute to a strategic effort to expand the chemical space relevant for antibacterial drug discovery and combat the growing threat of multidrug-resistant bacteria.

General Info

NIAID contracts for Chemistry Center to combat antibiotic-resistant bacteria over five years.

Agency

Department Of Health And Human Services → National Institutes Of Health Niaid

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)View NAICS

Place of Performance

Rockville, MD, 20852, USA

Set-Aside

NONE

Documents

(4)

Amendment No. 0002 to Solicitation 75N93024R00022

PDFamendment

Amendment+No.+0001-Signed.pdf

PDF

CC4CARB+JA+SAM+Posting.pdf

PDF

75N93024R00022-+Signed.pdf

PDF

AI Contract Breakdown

Uniform Contract Format

Sign up to view the full breakdown with detailed analysis of each section.

Timeline

2 updates
PhaseClosed
Type Changed

Presolicitation → Solicitation

Type Changed

Solicitation → special-notice

Amendment 3

Contract was updated

Posted

Presolicitation

Amendment 4

Contract was updated

Response Deadline

Deadline has passed

Submission Closed

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → National Institutes Of Health Niaid
Contacts2 people available
OfficeBETHESDA, MD, 20892, USA
Organization / Agency
Department Of Health And Human Services → National Institutes Of Health Niaid
Office AddressBETHESDA, MD, 20892, USA
Contacts

Full Description

Show more

The aim of this solicitation is to continue the Chemistry Center for Combating Antibiotic-Resistant Bacteria (CC4CARB) responsible for coordinating and conducting the design, synthesis, in vitro testing, and distribution of chemical libraries of discrete natural products and small-molecules with diverse physicochemical properties, specifically designed to target Gram-negative bacterial pathogens and other antibiotic-resistant bacteria identified as Antimicrobial Resistance threats. The contract shall consist of requirements in four (4) key areas: 1) Library Design, 2) Compound Synthesis, 3) Compound Testing, and 4) Compound Management, and includes Project Management of all efforts across these requirements.


Any responsible offeror may submit a proposal which will be considered by the Agency. This RFP will be available electronically on April 08, 2026, and may be accessed through https://sam.gov/.


Please note: After opening/downloading the solicitation in the Chrome browser, click the down arrow and select "Open with system viewer" to view the RFP in Adobe Acrobat. This process will allow the links in Section J of the RFP to work properly.


This notice does not commit the Government to award a contract. No collect calls will be accepted. No facsimile transmissions will be accepted.


For this solicitation, the NIAID requires proposals to be submitted online via the NIAID electronic Contract Proposal Submission (eCPS) website. Submission of proposals by facsimile or e-mail is not acceptable.


For directions on using eCPS, go to the website https://ecps.nih.gov/ and then click on "How to Submit."